← Back to Search

Ultrasound for Prostate Cancer

Phase 1
Waitlist Available
Led By Hossein Jadvar, MD
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial uses 18F-FMAU PET/CT to scan for prostate cancer. The tracer is given through a vein and helps to take pictures of areas inside the body where the tracer is taken up. This may help find the cancer and see how far the disease has spread.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of men for whom biopsy cores taken based only on the 18F-FMAU PET/CT results would have yielded the same overall diagnosis as the standard TRUS-guided core or the mpMRI-directed prostate biopsies
Malignant Neoplasms
Proportion of men who completed both imaging procedures and for whom biopsy cores taken based only on the fluorine 18F-FMAU PET/CT results would have yielded the same overall diagnosis as the standard TRUS-guided core prostate biopsies

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (18F-FMAU PET/CT)Experimental Treatment6 Interventions
Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CAT
2022
N/A
~1860
Multiparametric Magnetic Resonance Imaging
2021
Completed Early Phase 1
~10
Ultrasound
2013
Completed Phase 1
~4090
5-methyl-2'-fluoroarauracil F-18
Not yet FDA approved
Positron Emission Tomography
2008
Completed Phase 2
~2210

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
915 Previous Clinical Trials
1,603,706 Total Patients Enrolled
18 Trials studying Prostate Cancer
9,422 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,346 Total Patients Enrolled
565 Trials studying Prostate Cancer
529,064 Patients Enrolled for Prostate Cancer
National Institute for Biomedical Imaging and Bioengineering (NIBIB)NIH
89 Previous Clinical Trials
19,710 Total Patients Enrolled
5 Trials studying Prostate Cancer
175 Patients Enrolled for Prostate Cancer

Media Library

Ultrasound Clinical Trial Eligibility Overview. Trial Name: NCT02809690 — Phase 1
Prostate Cancer Research Study Groups: Diagnostic (18F-FMAU PET/CT)
Prostate Cancer Clinical Trial 2023: Ultrasound Highlights & Side Effects. Trial Name: NCT02809690 — Phase 1
Ultrasound 2023 Treatment Timeline for Medical Study. Trial Name: NCT02809690 — Phase 1
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top